专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2009106304A Improved method for bisulfite treatment 有权
标题翻译：改进的双螺杆菌治疗方法
公开(公告)号：JP2009106304A
公开(公告)日：2009-05-21
申请号：JP2009031400
申请日：2009-02-13
申请人： Epigenomics Ag , F Hoffmann La Roche Ag , エピジェノミクスアーゲー , エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft
发明人： MARKERT-HAHN CHRISTINE , BLOCK DIRK
IPC分类号： C12N15/09 , C07H21/00 , C12Q1/68
CPC分类号： C07H21/00 , C12Q1/6806 , C12Q1/6827 , C12Q1/6834 , C12Q2523/125 , C12Q2565/518
摘要： PROBLEM TO BE SOLVED: To provide a bisulfite reaction which can be readily performed manually, a bisulfite reaction using a solid phase, particularly magnetic glass particles, which is handleable by routine analytical equipment, and a bisulfite reaction performed successfully in a satisfying manner since the nucleic acid is bound to the surface of the solid phase by various interactions possibly influencing the success of the bisulfite reaction. SOLUTION: A method for the conversion of cytosine bases in a nucleic acid to uracil bases, wherein the nucleic acid is bound to a solid phase during a deamination step and/or a desulfonation step, the use of the solid phase in the nucleic acid during the deamination step and/or desulfonation step of the reaction in which cytosine bases in the nucleic acid are converted to uracil bases in the presence of bisulfite ion, and a kit for performing bisulfite reaction, containing a solution containing the bisulfite ion and a solid phase are provided. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：为了提供可以手动进行的亚硫酸氢盐反应，使用常规分析设备可处理的使用固相的特别是磁性玻璃颗粒的亚硫酸氢盐反应和亚硫酸氢盐反应在令人满意的情况下成功地进行因为核酸通过可能影响亚硫酸氢盐反应成功的各种相互作用结合到固相的表面。解决方案：将核酸中的胞嘧啶碱基转化为尿嘧啶碱的方法，其中在脱氨步骤和/或脱磺酸步骤期间核酸与固相结合，使用固相在在碱性步骤中的核酸和/或其中核酸中的胞嘧啶碱基在亚硫酸氢盐离子的存在下转化为尿嘧啶碱基的反应的脱磺酸步骤和用于进行亚硫酸氢盐反应的试剂盒，其包含含有亚硫酸氢盐离子的溶液和提供固相。版权所有（C）2009，JPO＆INPIT

2. 发明专利

JP2009261405A Improved method for treatment of bisulfite 审中-公开
标题翻译：改进双酚A的方法
公开(公告)号：JP2009261405A
公开(公告)日：2009-11-12
申请号：JP2009150412
申请日：2009-06-25
申请人： F Hoffmann La Roche Ag , エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft
发明人： BERGMANN FRANK , MARKET-HAHN CHRISTINE , KLEIBER JOERG , BLOCK DIRK
IPC分类号： C12Q1/68 , C01D5/00 , C01D5/14 , C07H21/04 , C12N15/09
CPC分类号： C07H21/04 , C01D5/145 , C12Q1/6827 , C12Q2527/101 , C12Q2523/125
摘要： PROBLEM TO BE SOLVED: To provide a method for performing a bisulfite reaction to determine methylation positions in a nucleic acid, i.e., methylated and non-methylated cytosines. SOLUTION: Provided is the method for performing a bisulfite reaction, whereby the nucleic acid is incubated in a solution comprising the nucleic acid for a time period of 1.5 to 3.5 hours at a temperature between 70 and 90°C, whereby the concentration of bisulfite in the solution is between 3 M and 6.25 M and whereby the pH value of the solution is between 5.0 and 6.0 whereby the nucleic acid, i.e., the cytosine bases in the nucleic acid, are deaminated. Then the solution comprising the deaminated nucleic acid is desulfonated. A kit comprising the solution having a specific pH value and the bisulfite is disclosed. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：待解决的问题：提供一种进行亚硫酸氢盐反应以确定核酸中甲基化位置的方法，即甲基化和非甲基化胞嘧啶。解决方案：提供了进行亚硫酸氢盐反应的方法，由此将核酸在包含核酸的溶液中在70至90℃的温度下温育1.5至3.5小时的时间段，由此浓度的亚硫酸氢盐在3 M和6.25 M之间，由此溶液的pH值在5.0和6.0之间，由此核酸，即核酸中的胞嘧啶碱基被脱氨。然后将包含脱氨酸核酸的溶液脱磺化。公开了包含具有特定pH值的溶液和亚硫酸氢盐的试剂盒。版权所有（C）2010，JPO＆INPIT

3. 发明专利

JP2004089195A Improved method for bisulfite treatment 有权
公开(公告)号：JP2004089195A
公开(公告)日：2004-03-25
申请号：JP2003306141
申请日：2003-08-29
申请人： F Hoffmann La Roche Ag , エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft
发明人： MARKERT-HAHN CHRISTINE , BLOCK DIRK
IPC分类号： C12N15/09 , C07H21/00
CPC分类号： C07H21/00 , C12Q1/6806 , C12Q1/6827 , C12Q1/6834 , C12Q2523/125 , C12Q2565/518
摘要： PROBLEM TO BE SOLVED: To provide bisulfite reaction capable of being easily conducted under manual operation, capable of using a solid phase, especially magnetic glass particles, which is treated with conventional analyzers, and capable of being successfully conducted in a satisfactory manner, because a nucleic acid is bound to surfaces of the solid phase by various interactions which have effects on success of the bisulfite reaction. SOLUTION: A method for transforming a cytosine base in the nucleic acid into a uracil base comprises binding the nucleic acid to the solid phase in a deamination process and/or in a desulfonation process. Further, the method for transforming the cytosine base in the nucleic acid into the uracil base comprises using the solid phase in the deamination process in which the cytosine base in the nucleic acid is transformed into the uracil base in the presence of bisulfite ions and/or in the desulfonation process. The kit for conducting the bisulfite reaction contains a solution containing the bisulfite ions and the solid phase. COPYRIGHT: (C)2004,JPO

4. 发明公开

KR20180051579A 수술 전 측정시 ＡＫＩ 의 위험 예측을 위한 ＩＧＦＢＰ７审中-公开
公开(公告)号：KR20180051579A
公开(公告)日：2018-05-16
申请号：KR20187009815
申请日：2016-10-10
申请人： HOFFMANN LA ROCHE
发明人： HORSCH ANDREA , KLAPPERICH BIRGIT , BLOCK DIRK , ENGEL ALFRED , KARL JOHANN , KIENTSCH ENGEL ROSEMARIE , MANUILOVA EKATERINA , RABE CHRISTINA , RUTZ SANDRA , SOUKUPOVA MONIKA , WIENHUES THELEN URSULA HENRIKE , KASTNER PETER , KAISER ANNA EDELGARD
IPC分类号： G01N33/68 , G01N33/74
CPC分类号： G01N33/68 , G01N33/6893 , G01N33/74
摘要： 본발명은외과적시술동안또는그 후에또는조영제투여후에급성신부전 (AKI) 을앓을위험을예측하는방법에관한것이다. 상기방법은외과적시술전 또는상기조영제투여전에환자로부터수득된체액시료에서바이오마커 IGFBP7 (인슐린유사성장인자결합단백질 7) 의수준결정을기반으로한다. 나아가, 본발명은환자로부터수득된체액시료에서의바이오마커 IGFBP7 (인슐린유사성장인자결합단백질 7) 및시스타틴 C 의양의결정을기반으로하는, 환자가급성신부전 (AKI) 을앓을위험을예측하는방법에관한것이다. 본발명은추가로본 발명의방법을수행하기위해제공되는키트및 장치를포함한다.

5. 发明申请

WO2015014794A8 USE OF ALPHA-CRYSTALLIN B (CRYAB) IN THE ASSESSMENT OF HEART FAILURE 审中-公开
标题翻译： ALPHA-CRYSTALLIN B（CRYAB）在心脏衰竭评估中的应用
公开(公告)号：WO2015014794A8
公开(公告)日：2015-08-13
申请号：PCT/EP2014066178
申请日：2014-07-28
申请人： HOFFMANN LA ROCHE , ROCHE DIAGNOSTICS GMBH , ROCHE DIAGNOSTICS OPERATIONS , UNIV TORONTO
发明人： WIENHUES-THELEN URSULA-HENRIKE , HESS GEORG , BLOCK DIRK , HUEDIG HENDRIK , EMILI ANDREW , GRAMOLINI ANTHONY , LIU PETER , MACLENNAN DAVID , ARAB SARA
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6887 , G01N2333/4712 , G01N2800/325
摘要： The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker CRYAB, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure selected from the group consisting of a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation, and of assessing heart failure by comparing the concentration determined in for CRYAB and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of CRYAB as a marker protein in the assessment of heart failure, a marker combination comprising CRYAB and a kit for measuring CRYAB.
摘要翻译：本发明涉及一种用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物CRYAB的浓度，任选地在样品中测量一种或多种其它心力衰竭标志物的浓度，所述其他标志物选自由利尿钠肽标记物，心肌肌钙蛋白标志物和炎症标志物组成的组，并且通过将对于CRYAB测定的浓度与对任选的一种或多种其它标记物测定的浓度与浓度的这种标记物或这些标记物在参考群体中建立。还公开了CRYAB作为评估心力衰竭的标记蛋白的用途，包括CRYAB的标记组合和用于测量CRYAB的试剂盒。

6. 发明申请

WO2010043393A8 USE OF BIGLYCAN IN THE ASSESSMENT OF HEART FAILURE 审中-公开
标题翻译：大智慧在评估心脏失败时的使用
公开(公告)号：WO2010043393A8
公开(公告)日：2011-02-24
申请号：PCT/EP2009007399
申请日：2009-10-15
申请人： ROCHE DIAGNOSTICS GMBH , HOFFMANN LA ROCHE , UNIV TORONTO , WIENHUES-THELEN URSULA-HENRIKE , ARAB SARA , BLOCK DIRK , EMILI ANDREW , GRAMOLINI ANTHONY , HESS GEORG , HUEDIG HENDRIK , LIU PETER , MACLENNAN DAVID
发明人： WIENHUES-THELEN URSULA-HENRIKE , ARAB SARA , BLOCK DIRK , EMILI ANDREW , GRAMOLINI ANTHONY , HESS GEORG , HUEDIG HENDRIK , LIU PETER , MACLENNAN DAVID
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4722 , G01N2800/325
摘要： The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker biglycan, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for biglycan and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of biglycan as a marker protein in the assessment of heart failure, a marker combination comprising biglycan and a kit for measuring biglycan.
摘要翻译：本发明涉及一种用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物双糖链球蛋白的浓度，任选地在样品中测量一种或多种其他心力衰竭标志物的浓度，以及通过将针对双糖链聚糖所测定的浓度与对任选的一种或多种其它标记物测定的浓度与参考群体中确定的该标志物或这些标记物的浓度进行比较来评估心力衰竭。还公开了在评估心力衰竭中使用双糖链蛋白聚糖作为标记蛋白，包括双糖链蛋白聚糖和用于测量双糖链球蛋白的试剂盒的标记物组合。

7. 发明申请

WO2015028469A3 MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE 审中-公开
标题翻译：心脏病治疗分层标志物在心力衰竭中的应用
公开(公告)号：WO2015028469A3
公开(公告)日：2015-05-07
申请号：PCT/EP2014068090
申请日：2014-08-26
申请人： ROCHE DIAGNOSTICS GMBH , HOFFMANN LA ROCHE , BLOCK DIRK , BRUNNER HANSPETER , DIETERLE THOMAS , WIENHUES-THELEN URSULA-HENRIKE , ZAUGG CHRISTIAN , ZIEGLER ANDRE
发明人： BLOCK DIRK , BRUNNER HANSPETER , DIETERLE THOMAS , WIENHUES-THELEN URSULA-HENRIKE , ZAUGG CHRISTIAN , ZIEGLER ANDRE
IPC分类号： G01N33/68 , A61K31/22
CPC分类号： G01N33/6893 , A61K31/40 , G01N33/62 , G01N33/6869 , G01N33/6872 , G01N2333/47 , G01N2333/475 , G01N2333/495 , G01N2333/5412 , G01N2800/325 , G01N2800/52
摘要： The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
摘要翻译：本发明涉及鉴定可能对含有他汀类药物的疗法有反应的心力衰竭患者的方法。该方法基于测量选自GDF-15（生长分化因子15），尿素，SHBG（性激素结合球蛋白），尿酸，PLGF（胎盘生长因子），IL-6（白细胞介素-6），转铁蛋白，心脏肌钙蛋白，sFlt-1（可溶性fms样酪氨酸激酶-1），前白蛋白，铁蛋白，骨桥蛋白，sST2（可溶性ST2）和hsCRP（高敏C反应蛋白）来自患者。进一步设想的是预测患者死亡或住院风险的方法，其中所述患者患有心力衰竭并且经历包含他汀的治疗。该方法也基于至少一个上述标记的水平的测量。

8. 发明申请

WO2011012268A1 USE OF MIMECAN IN THE ASSESSMENT OF HEART FAILURE 审中-公开
标题翻译： MIMEMAN在心力衰竭评估中的应用
公开(公告)号：WO2011012268A1
公开(公告)日：2011-02-03
申请号：PCT/EP2010004521
申请日：2010-07-23
申请人： ROCHE DIAGNOSTICS GMBH , HOFFMANN LA ROCHE , UNIV TORONTO , BLOCK DIRK , ARAB SARA , HESS GEORG , HUEDIG HENDRIK , LIU PETER , WIENHUES-THELEN URSULA-HENRIKE
发明人： BLOCK DIRK , ARAB SARA , HESS GEORG , HUEDIG HENDRIK , LIU PETER , WIENHUES-THELEN URSULA-HENRIKE
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4703 , G01N2800/325
摘要： The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker mimecan, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure selected from the group consisting of a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation, and of assessing heart failure by comparing the concentration determined in for mimecan and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan and a kit for measuring mimecan.
摘要翻译：本发明涉及一种体外评估心力衰竭的方法，其包括以下步骤：在样品中测量标志物mimecan的浓度，任选地在样品中测量一种或多种选自以下的一种或多种心力衰竭标志物的浓度：心肌肌钙蛋白标记物和炎症标记物组成的组，并且通过比较在mimecan中测定的浓度和针对任选的一种或多种其他标记物确定的浓度来评估心力衰竭该标记或这些标记在参照群体中建立。还公开了在评估心力衰竭时使用mimecan作为标记蛋白，包含mimecan的标记组合和用于测量mimecan的试剂盒。

9. 发明申请

WO2008089994A8 USE OF IGFBP-7 IN THE ASSESSMENT OF HEART FAILURE 审中-公开
标题翻译： IGFBP-7在心力衰竭评估中的应用
公开(公告)号：WO2008089994A8
公开(公告)日：2009-05-22
申请号：PCT/EP2008000576
申请日：2008-01-25
申请人： ROCHE DIAGNOSTICS GMBH , HOFFMANN LA ROCHE , UNIV TORONTO , WIENHUES-THELEN URSULA-HENRIKE , BLOCK DIRK , EMILI ANDREW , FONG VINCENT , GRAMOLINI ANTHONY , HESS GEORG , HUEDIG HENDRIK , ISSERLIN RUTH , KISLINGER THOMAS , LIU PETER , MACLENNAN DAVID , ELTZ HERBERT VON DER
发明人： WIENHUES-THELEN URSULA-HENRIKE , BLOCK DIRK , EMILI ANDREW , FONG VINCENT , GRAMOLINI ANTHONY , HESS GEORG , HUEDIG HENDRIK , ISSERLIN RUTH , KISLINGER THOMAS , LIU PETER , MACLENNAN DAVID , VON DER ELTZ HERBERT
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/47 , G01N2333/4727 , G01N2333/4737 , G01N2333/4745 , G01N2333/5412 , G01N2333/58 , G01N2800/325 , G01N2800/56
摘要： The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
摘要翻译：本发明涉及用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物IGFBP-7的浓度，任选地在样品中测量一种或多种其他心力衰竭标志物的浓度，并且通过比较在IGFBP-7中测定的浓度和为任选的一种或多种其它标记确定的浓度与在参考群体中确定的该标志物或这些标记物的浓度进行比较来评估心力衰竭。还公开了在评估心力衰竭中使用IGFBP-7作为标记蛋白，包括IGFBP-7的标记组合和用于测量IGFBP-7的试剂盒。

10. 发明专利

ES2823124T3 Angiopoyetina-2 (Ang-2) circulante para la predicción de recidiva de fibrilación auricular 未知
公开(公告)号：ES2823124T3
公开(公告)日：2021-05-06
申请号：ES17733406
申请日：2017-06-19
申请人： HOFFMANN LA ROCHE
发明人： ANDRES HERBERT , BLOCK DIRK , KARL JOHANN , KASTNER PETER , WIENHUES-THELEN URSULA-HENRIKE , LATINI ROBERTO , MASSON SERGE , ZIEGLER ANDRÉ , KAISER EDELGARD , PALME STEFAN , THOMAS MARKUS , BARLERA SIMONA
IPC分类号： G01N33/68
摘要： Un procedimiento para predecir el riesgo de recidiva de fibrilación auricular en un sujeto, comprendiendo dicho procedimiento la determinación de la cantidad del biomarcador angiopoyetina-2 (Ang-2) y opcionalmente la determinación de la cantidad de al menos otro biomarcador seleccionado del grupo que consiste en angiopoyetina-1(Ang-1), un péptido de tipo BNP, CK-MB (creatina cinasa de tipo muscular-cerebral), IGFBP-7 (proteína de unión al factor de crecimiento insulínico 7) y una troponina cardíaca en una muestra de sangre, suero o plasma del sujeto.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式